Back to School: How biopharma can reboot drug development. Access exclusive analysis here
In a 6-month Phase III study of 328 Type I diabetes patients, Exubera before meals plus 2 daily insulin injections
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury